Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
Shapiro AD, Di Paola J, Cohen A, Pasi KJ, Heisel MA, Blanchette VS, Abshire TC, Hoots WK, Lusher JM, Negrier C, Rothschild C, Roth DA. Shapiro AD, et al. Among authors: blanchette vs. Blood. 2005 Jan 15;105(2):518-25. doi: 10.1182/blood-2004-06-2283. Epub 2004 Sep 21. Blood. 2005. PMID: 15383463 Free article. Clinical Trial.
Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.
Ewenstein BM, Collins P, Tarantino MD, Negrier C, Blanchette V, Shapiro AD, Baker D, Spotts G, Sensel M, Yi SE, Gomperts ED. Ewenstein BM, et al. Semin Hematol. 2004 Jan;41(1 Suppl 2):1-16; discussion 16-8. doi: 10.1016/s0037-1963(04)00017-4. Semin Hematol. 2004. PMID: 15071785
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM; Advate Clinical Program Group; Collins PW. Björkman S, et al. Among authors: blanchette vs. J Thromb Haemost. 2010 Apr;8(4):730-6. doi: 10.1111/j.1538-7836.2010.03757.x. J Thromb Haemost. 2010. PMID: 20398185 Free PMC article.
Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.
Neunert CE, Buchanan GR, Imbach P, Bolton-Maggs PH, Bennett CM, Neufeld EJ, Vesely SK, Adix L, Blanchette VS, Kühne T; Intercontinental Childhood ITP Study Group Registry II Participants. Neunert CE, et al. Among authors: blanchette vs. Blood. 2008 Nov 15;112(10):4003-8. doi: 10.1182/blood-2008-03-138487. Epub 2008 Aug 12. Blood. 2008. PMID: 18698007 Free PMC article.
311 results